Novartis stakes another PhIII win for Cosentyx, goes deeper into pediatric markets

Just hours after the FDA cleared Novartis’ Cosentyx for its first pediatric indication, the company is following up with more positive data on another: juvenile idiopathic arthritis, or JIA.

The results from the Phase III JUNIPERA study, Novartis says, pave the way for regulatory submissions slated...

Click to view original post